Flex Pharma, Inc. today announced that approximately 85% of shares voted to date support the proposed merger with Salarius Pharmaceuticals, LLC, an epigenetic oncology company. However, in order to complete the merger, a quorum must be present at the special meeting (in person or by proxy) and a majority of outstanding shares must approve Proposal 2, which is described in Flex Pharma’s proxy statement/prospectus/information statement.
Flex Pharma adjourned the special meeting until July 12, 2019 in order to provide shareholders with more time to complete proxies and vote their shares.
Flex Pharma’s CEO William McVicar stated, “We are very pleased that the vast majority of shareholders who voted support the merger with Salarius, consistent with the recommendations of both leading, independent proxy advisory services ISS and Glass-Lewis.” Flex Pharma’s Board of Directors also unanimously recommends voting “FOR” all proposals in the proxy statement/prospectus/information statement as the best way to preserve future shareholder value.
Additional shares must be voted in order to complete the planned merger with Salarius Pharmaceuticals, LLC, a privately held clinical-stage oncology company targeting the epigenetic causes of cancers.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
ADDITIONAL VOTES ARE REQUIRED TO COMPLETE THE MERGER
– URGENT ACTION NEEDED BEFORE July 12, 2019 –
All shareholders are urged to vote as soon as possible “FOR” all proposals in the proxy statement/prospectus/information statement by telephone, via the Internet or using the proxy card they received with their proxy materials. For any questions, or assistance in voting shares, or to receive additional copies of the proxy materials, shareholders should call Flex Pharma’s proxy solicitor, Innisfree M&A Incorporated, toll-free at 1 (888) 750-5834.
Date: June 24, 2019
Source: Yahoo Finance